Member   |  中文 | English

Welcome to Xi’an Good Doctor Medical Science and Technology Co., Ltd.

Service Hotline:

+86 29 82681864 

Online customer service
Service Hotline:
+86 29 82681864
Customer service team:
Online Service:
Service time:
8:00 - 24:00

Tel: +86 29 82681864   +86 15002902555 Fax: +86 29 82681864

E-mail: gd_hipec@126.com

Add: Building 1, Huoju Road, East zone of Xi’an High-tech Development District, Xi'an, China

WeChat

Mobile

News 

HIPEC Improves Ovarian Cancer Survival

Author:
Source:
2019/09/04
Page view
  HIPEC Improves Ovarian Cancer Survival
 
  KRISTIE L . KAHL
 
  Wednesday , February 28 , 2018
 
  Women with stage 3 epithelial ovarian cancer could benefit from the addition of hyperthermic intraperitoneal chemotherapy ( HIPEC ) , also known as a hot chemotherapy bath . Study results published in the New England Journal of Medicine showed that HIPEC improved survival rates by 10% . 
 
  Patients with newly diagnosed advanced-stage ovarian cancer are often treated with cytoreductive surgery and systemic chemotherapy . Patients either start with an operation followed by 6 courses of chemotherapy , or primary debulking , or they are given 3 courses of chemotherapy before surgery and 3 more courses after , also known as interval debulking .
 
  With these treatment options , only one-third of patients are still alive after 5 years , according to a Netherlands Cancer Institute press release . 
 
  Therefore , researchers in the Netherlands investigated whether the addition of HIPEC to interval debulking would improve outcomes among patients who were receiving neoadjuvant chemotherapy as treatment for stage 3 epithelial ovarian cancer .
 
  “ Ten years ago , we wanted to find out what the effect was of HIPEC for patients with ovarian carcinoma , ” lead author Willemien J . van Driel , MD , PhD , from the Department of Gynecology at the Netherlands Cancer Institute in Amsterdam , said in an interview with Oncology Nursing News . “ We had the results of the colon HIPEC trial which were positive , and we had the results of the Armstrong trial who showed a longer survival for patients receiving postoperative intraperitoneal chemotherapy . ”
 
  In a multicenter , open-label , phase 3 trial , the researchers randomly assigned 245 patients to undergo interval debulking either with or without administration of HIPEC with cisplatin . Three additional cycles of carboplatin and paclitaxel were administered postoperatively . 
 
  The researchers specifically looked at recurrence-free survival , as well as overall survival ( OS ) and safety . 
 
  Events of disease recurrence or death occurred in 110 of the 123 patients who underwent surgery without HIPEC and in 99 of the 122 patients who had surgery plus HIPEC . 
 
  Patients treated with hot chemotherapy bath experienced longer recurrence-free survival ( 14 . 2 months ) compared with patients who did not ( 10.7 months ) . 
 
  After a follow-up of 4 . 7 years , 76 patients in the control arm ( 62% ) and 61 patients who received HIPEC ( 50% ) died . The group of patients who receive d hot chemotherapy bath also experienced longer OS compared with the control arm ( 45 . 7 months vs . 33 . 9 months ) . 
 
  “ Adding HIPEC to interval debulking improved both recurrence free survival and overall survival without increasing morbidity , ” said van Driel . 
 
  There was no difference in adverse events ( AEs ) among groups , and HIPEC appeared well-tolerated . 
 
  As a result of the study , the guidelines committee for gynecological oncology in the Netherlands will be discussing whether to add HIPEC as a standard of care . However , van Driel noted oncology staff will need to be trained because this is a complicated procedure . 
 
  “ In the Netherlands we are in the process of adjusting the guidelines at this point , ” she added . “ Once the literature search supports the result of the trial we will want to implement it as standard of care . It will be difficult to repeat this trial with this number of patients and the results are convincing . ”
 
  新闻来源网站:
 
  https : // www . oncnursingnews . com / web-exclusives / hipec-improves-ovarian-cancer-survival